TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
2024年4月8日 - 9:00PM
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage
biopharmaceutical company focused on the development of T cell
receptor (TCR)-engineered T cell therapies (TCR-T) for the
treatment of patients with cancer, today announced the appointment
of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr.
Louis has extensive experience in hematology and oncology drug
development, with a track record of success in clinical
development, medical affairs, and commercialization.
“We are excited to welcome Chrystal to TScan at
this critical time as we continue to progress both clinical-stage
programs in heme malignancies and solid tumors. Chrystal’s
expertise, spanning all phases of drug development from Phase 1
studies to commercialization and life-cycle management, will be
invaluable at this stage of rapid growth for the Company,” said
Gavin MacBeath, Ph.D., Chief Executive Officer. “I look forward to
working with Chrystal as we strive to realize the full potential of
our pipeline. On behalf of our Board and our team, I would like to
thank Dr. Debora Barton for her key contributions that have enabled
us to deliver positive data from our heme program and initiate our
solid tumor program.”
“I am thrilled to join the TScan team at such an
exciting time as we continue to build on the success seen to date
in the heme program and as momentum builds in the solid tumor
program,” said Dr. Louis. “I look forward to leveraging my previous
experience to support the advancement of these novel cell therapies
as we aim to deliver life-changing therapies to patients in
need.”
Dr. Louis is succeeding Debora Barton, M.D., who
has served as the Company’s Chief Medical Officer since July 2022.
Dr. Barton is departing TScan for personal reasons and will
continue to advise the Company as a consultant to ensure a smooth
transition of responsibilities. "Transitioning out of my role at
TScan has been a difficult decision,” said Dr. Barton. “It has been
a pleasure working with this dynamic team and I am proud of the
progress we have made collectively with our clinical programs. I
look forward to following the future success of the Company.”
Dr. Louis joins TScan with two decades of
experience across academia and industry where she built and managed
high-performing clinical and medical affairs teams and worked on
multiple regulatory approvals, new product launches, and strategies
for label expansion. Prior to joining TScan, Dr. Louis was the SVP
of hematology clinical development at Zentalis Pharmaceuticals. Dr.
Louis held roles of increasing responsibility within medical
affairs at CRISPR Therapeutics, Bristol Myers Squibb Company (BMS),
and Celgene (acquired by BMS), as well as clinical development and
project leadership at Merrimack Pharmaceuticals. Throughout the
course of her career, she has been responsible for the design and
oversight of clinical programs, medical strategy, and launch
activities of novel therapeutic agents that have spanned small
molecules to cell and gene therapies. Prior to joining industry,
Dr. Louis was an Assistant Professor at Texas Children’s Cancer
Center and Hematology Service, Baylor College of Medicine, where
she worked on the early development of CAR-T cell therapy products
for solid tumor malignancies. Dr. Louis received her M.D. from
Tulane University School of Medicine, her Masters Degree in Public
Health from Tulane University School of Public Health and Tropical
Medicine, and her B.A. in Political Science and B.S. in Chemistry
from Southwestern University at Georgetown, TX.
About TScan Therapeutics,
Inc.
TScan is a clinical-stage biopharmaceutical
company focused on the development of T cell receptor
(TCR)-engineered T cell therapies (TCR-T) for the treatment of
patients with cancer. The Company’s lead TCR-T candidates, TSC-100
and TSC-101, are in development for the treatment of patients with
hematologic malignancies to prevent relapse following allogeneic
hematopoietic cell transplantation. The Company is also developing
multiplexed TCR-T candidates for the treatment of various solid
tumors. The Company has developed and continues to expand its
ImmunoBank, the Company’s repository of therapeutic TCRs that
recognize diverse targets and are associated with multiple HLA
types, to provide customized multiplex therapeutic TCR-Ts for
patients with a variety of cancers.
Forward-Looking Statements
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, express or implied
statements regarding the Company’s plans, progress, and timing
relating to the Company’s hematologic malignancies and solid tumor
programs; the potential benefits of any of the Company’s
proprietary platforms, multiplexing, or current or future product
candidates in treating patients; and the Company’s goals, strategy,
and focus. TScan intends such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by terms
such as, but not limited to, “may,” “might,” “will,” “objective,”
“intend,” “should,” “could,” “can,” “would,” “expect,” “believe,”
“anticipate,” “project,” “target,” “design,” “estimate,” “predict,”
“potential,” “plan,” “on track,” or similar expressions or the
negative of those terms. Such forward-looking statements are based
upon current expectations that involve risks, changes in
circumstances, assumptions, and uncertainties. The express or
implied forward-looking statements included in this release are
only predictions and are subject to a number of risks,
uncertainties and assumptions, including, without limitation: the
beneficial characteristics, safety, efficacy, therapeutic effects
and potential advantages of TScan’s TCR-T therapy candidates;
TScan’s expectations regarding its preclinical studies being
predictive of clinical trial results; TScan’s recently approved
INDs being indicative or predictive of bringing TScan closer to its
goal of providing customized TCR-T therapies to treat patients with
cancer; the timing of the launch, initiation, progress, expected
results and announcements of TScan’s preclinical studies, clinical
trials and its research and development programs; TScan’s timeline
regarding its filing of INDs for its TCRs throughout the year;
TScan’s ability to enroll patients for its clinical trials within
its expected timeline; TScan’s plans relating to developing and
commercializing its TCR-T therapy candidates, if approved,
including sales strategy; estimates of the size of the addressable
market for TScan’s TCR-T therapy candidates; TScan’s manufacturing
capabilities and the scalable nature of its manufacturing process;
TScan’s estimates regarding expenses, future milestone payments and
revenue, capital requirements and needs for additional financing;
TScan’s expectations regarding competition; TScan’s anticipated
growth strategies; TScan’s ability to attract or retain key
personnel; TScan’s ability to establish and maintain development
partnerships and collaborations; TScan’s expectations regarding
federal, state and foreign regulatory requirements; TScan’s ability
to obtain and maintain intellectual property protection for its
proprietary platform technology and our product candidates; the
sufficiency of TScan’s existing capital resources to fund its
future operating expenses and capital expenditure requirements; and
other factors that are described in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of TScan’s most recent Annual
Report on Form 10-K and any other filings that TScan has made or
may make with the SEC in the future. Any forward-looking statements
contained in this release represent TScan’s views only as of the
date hereof and should not be relied upon as representing its views
as of any subsequent date. Except as required by law, TScan
explicitly disclaims any obligation to update any forward-looking
statements.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP,
Investor Relations857-399-9840hsavelle@tscan.com
Melissa ForstArgot
Partners212-600-1902TScan@argotpartners.com
TScan Therapeutics (NASDAQ:TCRX)
過去 株価チャート
から 8 2024 まで 9 2024
TScan Therapeutics (NASDAQ:TCRX)
過去 株価チャート
から 9 2023 まで 9 2024